2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Acute Pain D059787 3 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
Hutchins-Wiese HL et al. Hind limb suspension and long-chain omega-3 PUFA increase mRNA endocannabinoid system levels in skeletal muscle. 2012 J. Nutr. Biochem. pmid:22051448
Heyman E et al. Intense exercise increases circulating endocannabinoid and BDNF levels in humans--possible implications for reward and depression. 2012 Psychoneuroendocrinology pmid:22029953
Chang JW et al. Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. 2012 Chem. Biol. pmid:22542104
Atwood BK et al. CBâ‚‚ cannabinoid receptors inhibit synaptic transmission when expressed in cultured autaptic neurons. 2012 Neuropharmacology pmid:22579668
Spivak CE et al. Blockade of β-cell K(ATP) channels by the endocannabinoid, 2-arachidonoylglycerol. 2012 Biochem. Biophys. Res. Commun. pmid:22609205
Chon SH et al. Over-expression of monoacylglycerol lipase (MGL) in small intestine alters endocannabinoid levels and whole body energy balance, resulting in obesity. 2012 PLoS ONE pmid:22937137
Thomas KC et al. Contributions of TRPV1, endovanilloids, and endoplasmic reticulum stress in lung cell death in vitro and lung injury. 2012 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:21949157
Woodhams SG et al. Spinal administration of the monoacylglycerol lipase inhibitor JZL184 produces robust inhibitory effects on nociceptive processing and the development of central sensitization in the rat. 2012 Br. J. Pharmacol. pmid:22924700
Schulte K et al. Cannabinoid CB1 receptor activation, pharmacological blockade, or genetic ablation affects the function of the muscarinic auto- and heteroreceptor. 2012 Naunyn Schmiedebergs Arch. Pharmacol. pmid:22215206
Gatta-Cherifi B et al. Simultaneous postprandial deregulation of the orexigenic endocannabinoid anandamide and the anorexigenic peptide YY in obesity. 2012 Int J Obes (Lond) pmid:21844878
Oleson EB et al. Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum. 2012 Neuron pmid:22284189
Echigo R et al. Cannabinoids inhibit peptidoglycan-induced phosphorylation of NF-κB and cell growth in U87MG human malignant glioma cells. 2012 Oncol. Rep. pmid:22842590
Kortleven C et al. Neurotensin inhibits glutamate-mediated synaptic inputs onto ventral tegmental area dopamine neurons through the release of the endocannabinoid 2-AG. 2012 Neuropharmacology pmid:22884466
Petrovszki Z et al. The effects of peptide and lipid endocannabinoids on arthritic pain at the spinal level. 2012 Anesth. Analg. pmid:22451592
Tanimura A et al. Synapse type-independent degradation of the endocannabinoid 2-arachidonoylglycerol after retrograde synaptic suppression. 2012 Proc. Natl. Acad. Sci. U.S.A. pmid:22783023
Monteleone P et al. Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study. 2012 J. Clin. Endocrinol. Metab. pmid:22442280
Strewe C et al. Effects of parabolic flight and spaceflight on the endocannabinoid system in humans. 2012 Rev Neurosci pmid:23023882
Whyte LS et al. Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro. 2012 Br. J. Pharmacol. pmid:21649637
Skaper SD and Di Marzo V Endocannabinoids in nervous system health and disease: the big picture in a nutshell. 2012 Philos. Trans. R. Soc. Lond., B, Biol. Sci. pmid:23108539
Booker L et al. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. 2012 Br. J. Pharmacol. pmid:21506952
Di Marzo V and De Petrocellis L Why do cannabinoid receptors have more than one endogenous ligand? 2012 Philos. Trans. R. Soc. Lond., B, Biol. Sci. pmid:23108541
Puighermanal E et al. Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids. 2012 Philos. Trans. R. Soc. Lond., B, Biol. Sci. pmid:23108544
Starowicz K and Przewlocka B Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system. 2012 Philos. Trans. R. Soc. Lond., B, Biol. Sci. pmid:23108547
Rani Sagar D et al. Dynamic changes to the endocannabinoid system in models of chronic pain. 2012 Philos. Trans. R. Soc. Lond., B, Biol. Sci. pmid:23108548
Navia-Paldanius D et al. Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12). 2012 J. Lipid Res. pmid:22969151
Zoerner AA et al. Simultaneous UPLC-MS/MS quantification of the endocannabinoids 2-arachidonoyl glycerol (2AG), 1-arachidonoyl glycerol (1AG), and anandamide in human plasma: minimization of matrix-effects, 2AG/1AG isomerization and degradation by toluene solvent extraction. 2012 J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. pmid:21752730
Ueda N et al. Biosynthesis and degradation of the endocannabinoid 2-arachidonoylglycerol. 2011 Jan-Feb Biofactors pmid:21328621
Nomura DK et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. 2011 Science pmid:22021672
Muppidi JR et al. Cannabinoid receptor 2 positions and retains marginal zone B cells within the splenic marginal zone. 2011 J. Exp. Med. pmid:21875957
Duggan KC et al. (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. 2011 Nat. Chem. Biol. pmid:22053353
Puente N et al. Polymodal activation of the endocannabinoid system in the extended amygdala. 2011 Nat. Neurosci. pmid:22057189
Stella N Cell biology. Anatomy of prostaglandin signals. 2011 Science pmid:22076368
Patsenker E et al. Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. 2011 Mol. Med. pmid:21863215
Hill MN et al. Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. 2011 J. Neurosci. pmid:21775596
Bari M et al. Characterization of the endocannabinoid system in mouse embryonic stem cells. 2011 Stem Cells Dev. pmid:20446814
Chanda D et al. Cannabinoid receptor type 1 (CB1R) signaling regulates hepatic gluconeogenesis via induction of endoplasmic reticulum-bound transcription factor cAMP-responsive element-binding protein H (CREBH) in primary hepatocytes. 2011 J. Biol. Chem. pmid:21693703
Signorello MG et al. Activation of human platelets by 2-arachidonoylglycerol: role of PKC in NO/cGMP pathway modulation. 2011 Curr Neurovasc Res pmid:21675954
Marrs WR et al. Dual inhibition of alpha/beta-hydrolase domain 6 and fatty acid amide hydrolase increases endocannabinoid levels in neurons. 2011 J. Biol. Chem. pmid:21665953
Gantayet A et al. Endocannabinoids and diacylglycerol kinase activity. 2011 Biochim. Biophys. Acta pmid:21194521
Duclos RI et al. A methodology for radiolabeling of the endocannabinoid 2-arachidonoylglycerol (2-AG). 2011 J. Org. Chem. pmid:21370840
Shimizu T et al. Endogenously generated 2-arachidonoylglycerol plays an inhibitory role in bombesin-induced activation of central adrenomedullary outflow in rats. 2011 Eur. J. Pharmacol. pmid:21371452
Lourbopoulos A et al. Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. 2011 Brain Res. pmid:21406188
Kortleven C et al. The endocannabinoid 2-arachidonoylglycerol inhibits long-term potentiation of glutamatergic synapses onto ventral tegmental area dopamine neurons in mice. 2011 Eur. J. Neurosci. pmid:21410793
Oudin MJ et al. Endocannabinoids regulate the migration of subventricular zone-derived neuroblasts in the postnatal brain. 2011 J. Neurosci. pmid:21411643
Hashimotodani Y et al. Neuronal protease-activated receptor 1 drives synaptic retrograde signaling mediated by the endocannabinoid 2-arachidonoylglycerol. 2011 J. Neurosci. pmid:21414931
Taschler U et al. Monoglyceride lipase deficiency in mice impairs lipolysis and attenuates diet-induced insulin resistance. 2011 J. Biol. Chem. pmid:21454566
Mulder J et al. Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. 2011 Brain pmid:21459826
Vecchio AJ and Malkowski MG The structural basis of endocannabinoid oxygenation by cyclooxygenase-2. 2011 J. Biol. Chem. pmid:21489986
Di Marzo V Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. 2011 Nat. Neurosci. pmid:21187849
Quercioli A et al. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. 2011 Eur. Heart J. pmid:21303779